4’-(dimethylamino)-[1,1’-biphenyl]-4-carbaldehyde | 173991-06-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4’-(dimethylamino)-[1,1’-biphenyl]-4-carbaldehyde
• 英文别名: 4’-(dimethylamino)-[1,1'-biphenyl]-4-carbaldehyde；4'-(dimethylamino)-[1,1'-biphenyl]-4-carbaldehyde；4'-(dimethylamino)[1,1'-biphenyl]-4-carbaldehyde；4'-(N,N-dimethylamino)biphenyl-4-carbaldehyde；4-formyl-4'-(N,N-dimethylamino)-1,1'-biphenyl；4'-(dimethylamino)biphenyl-4-carbaldehyde；4-[4-(Dimethylamino)phenyl]benzaldehyde
• CAS: 173991-06-5
• 化学式: C₁₅H₁₅NO
• mdl: MFCD06801749
• 分子量: 225.29
• InChiKey: CPIVRXYXECSDDK-UHFFFAOYSA-N

物化性质

• 沸点：
  386.5±35.0 °C(Predicted)
• 密度：
  1.102±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4’-(dimethylamino)-[1,1’-biphenyl]-4-carbaldehyde 在 sodium tetrahydroborate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 1-Cycloheptyl-1-[[4-[4-(dimethylamino)phenyl]phenyl]methyl]-3-(2,4,6-trimethylphenyl)urea
  参考文献：
  名称：

  Inhibitors of acyl-CoA: cholesterol O-acyltransferase (ACAT). Part 1: Identification and structure-activity relationships of a novel series of substituted N-alkyl-N-biphenylylmethyl-N′-arylureas

  摘要：

  A series of N-alkyl-N-biphenylylmethyl-N'-arylurea and related derivatives represented by 1 have been prepared and evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Linking of two phenyl groups via oxygen and introduction of fluorine at appropriate positions on the biphenyl moiety improved in vitro and in vivo activity, From this series of analogs, compound 40 (FR179254), which had potent in vitro potency (rabbit intestinal microsomes IC50 = 25 nM), showed excellent plasma cholesterol-lowering activity when administered via the diet (ED50 = 0.045 mg/kg). However, the hypocholesterolemic effect of this compound was moderate when dosed by oral gavage in PEG400 as a vehicle (ED50 = 5.3 mg/kg). Modification of the N'-aryl moiety led to the identification of compound 50 (FR182980) which was efficacious in both dosing models (ED50 = 0.034 mg/kg and 0.11 mg/kg, respectively). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(97)10009-8
• 作为产物：
  描述：

  4-羧基苯硼酸 在 四(三苯基膦)钯 lithium aluminium tetrahydride 、 sodium carbonate 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 为溶剂， 反应 90.5h， 生成 4’-(dimethylamino)-[1,1’-biphenyl]-4-carbaldehyde
  参考文献：
  名称：

  Inhibitors of acyl-CoA: cholesterol O-acyltransferase (ACAT). Part 1: Identification and structure-activity relationships of a novel series of substituted N-alkyl-N-biphenylylmethyl-N′-arylureas

  摘要：

  A series of N-alkyl-N-biphenylylmethyl-N'-arylurea and related derivatives represented by 1 have been prepared and evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Linking of two phenyl groups via oxygen and introduction of fluorine at appropriate positions on the biphenyl moiety improved in vitro and in vivo activity, From this series of analogs, compound 40 (FR179254), which had potent in vitro potency (rabbit intestinal microsomes IC50 = 25 nM), showed excellent plasma cholesterol-lowering activity when administered via the diet (ED50 = 0.045 mg/kg). However, the hypocholesterolemic effect of this compound was moderate when dosed by oral gavage in PEG400 as a vehicle (ED50 = 5.3 mg/kg). Modification of the N'-aryl moiety led to the identification of compound 50 (FR182980) which was efficacious in both dosing models (ED50 = 0.034 mg/kg and 0.11 mg/kg, respectively). (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(97)10009-8

文献信息

• [EN] FARNESOID X RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR X FARNÉSOÏDE ET LEURS UTILISATIONS
  申请人：METACRINE INC

  公开号：WO2017049177A1

  公开（公告）日：2017-03-23

  Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

  本发明涉及法尼醇X受体激动剂化合物，制造此类化合物的方法，包含此类化合物的药物组合物和药品，以及使用此类化合物治疗与法尼醇X受体活性相关的状况、疾病或失调的方法。
• Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17)—Part II: Core rigidification and influence of substituents at the methylene bridge
  作者：Qingzhong Hu、Matthias Negri、Kerstin Jahn-Hoffmann、Yan Zhuang、Sureyya Olgen、Marc Bartels、Ursula Müller-Vieira、Thomas Lauterbach、Rolf W. Hartmann

  DOI：10.1016/j.bmc.2008.07.011

  日期：2008.8

  Thirty-five novel substituted imidazolyl methylene biphenyls have been synthesized as CYP17 inhibitors for the potential treatment of prostate cancer. Their activities have been tested with recombinant human CYP17 expressed in Escherichia coli. Promising compounds were tested for selectivity against CYP11B1, CYP11B2, and hepatic CYP enzymes 3A4, 1A2, 2B6 and 2D6. The core rigidified compounds (30-35)

  已合成了35种新型取代的咪唑基亚甲基联苯作为CYP17抑制剂，可用于治疗前列腺癌。已经用在大肠杆菌中表达的重组人CYP17测试了它们的活性。测试了有前途的化合物对CYP11B1，CYP11B2和肝CYP酶3A4、1A2、2B6和2D6的选择性。核心刚性化合物（30-35）是最活跃的化合物，比酮康唑更有效，并达到阿比特龙的活性。但是，它们不是非常有选择性。在大鼠中进一步检查了血浆中睾丸激素水平和药代动力学特性的另一种更有效且更具选择性的抑制剂（化合物23，IC（50）= 345 nM）。相较于参考文献Abiraterone，体内有23种活性更高，显示更长的血浆半衰期（10小时）和更高的生物利用度。使用我们的CYP17同源蛋白模型，与选定化合物进行对接研究，以研究抑制剂与活性位点氨基酸残基之间的可能相互作用。
• 新規アミド誘導体
  申请人：株式会社富士薬品

  公开号：JP2021109846A

  公开（公告）日：2021-08-02

  【課題】ＦＸＲアゴニスト作用及びＴＧＲ５（ＧＰＢＡＲ）アゴニスト作用を有する新規アミド誘導体又はその塩、及びそれらを含有する医薬組成物の提供。【解決手段】下記一般式（Ｉ）で表される新規アミド誘導体、又はその医薬上許容される塩。［Ｒ１〜Ｒ４は、各々独立にハロゲン原子、置換／非置換のＣ１−Ｃ６アルキル基等；環Ａ、環Ｄは、各々独立にアリール環、ヘテロアリール環；環Ｂは、アリール環、ヘテロアリール環、飽和炭化水素環；ｍは、１〜４の整数；ｎ、ｐ、ｑは、各々独立に０〜４の整数；Ｘ，Ｙは、Ｃ又はＮ］【選択図】なし

  提供具有FXR激动剂作用和TGR5（GPBAR）激动剂作用的新酰胺衍生物或其盐，以及含有它们的药物组合物。新的酰胺衍生物由下述通式（I）表示，或其药用上可接受的盐。[R1-R4分别独立表示卤原子，取代/未取代的C1-C6烷基等；环A、环D分别独立表示芳基环，杂环芳基环；环B表示芳基环，杂环芳基环，饱和碳氢环；m为1-4的整数；n、p、q分别独立表示0-4的整数；X，Y为C或N]【选择图】无
• N,N′-Dibutylbarbituric acid as an acceptor moiety in push–pull chromophores
  作者：Milan Klikar、Filip Bureš、Oldřich Pytela、Tomáš Mikysek、Zdeňka Padělková、Alberto Barsella、Kokou Dorkenoo、Sylvain Achelle

  DOI：10.1039/c3nj00683b

  日期：——

  Twelve novel D–π–A chromophores with the N,N′-dibutylbarbituric acid acceptor, the N,N-dimethylamino donor and a systematically extended π-linker were synthesized. The extent of intramolecular charge-transfer, structure–property relationships and nonlinear optical properties were further investigated by X-ray analysis, electrochemistry, UV/Vis absorption spectra, calculations and EFISH experiments.

  合成了具有N，N'-二丁基巴比妥酸受体、N，N-二甲基氨基供体和系统性延长的π连接体的十二种新型D-π-A型色团。通过X射线分析、电化学、紫外/可见吸收光谱、计算和EFISH实验进一步研究了分子内电荷转移程度、结构-性质关系和非线性光学性质。
• [EN] HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES MIMÉTIQUES DES FACTEURS DE CROISSANCE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2011046954A1

  公开（公告）日：2011-04-21

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  目前的实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。目前的实施例还涉及利用这些化合物来治疗各种疾病、疾病和疾患，如造血状况和疾病。